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AbstrACt
Objectives To assess the impact of both the Committee 
on Safety of Medicines (CSM) warning (December 2003) 
and the National Institute for Health and Care Excellence 
(NICE) guidance (September 2005) on antidepressant 
prescription rates in children and adolescents within the 
UK primary care service.
setting Population based study of primary care 
antidepressant prescribing using the Clinical Practice 
Research Datalink (CPRD).
Participants Under-18s presenting to primary care with 
a depressive disorder or related diagnostic code recorded 
in the CPRD.
Primary outcome measure Antidepressant prescription 
rates per month per 100 000 depressed 4–17 year olds.
results Following the CSM warning, the prior trend 
towards increased prescribing rates for selective serotonin 
reuptake inhibitors (SSRIs) in children was significantly 
reversed (β for change in trend −12.34 (95% CI −18.67 
to −6.00, p<0.001)). However, after the publication of 
the NICE guidelines the prior trend towards increased 
prescribing resumed for those SSRIs mentioned as 
potential treatments in the guidance (fluoxetine, citalopram 
and sertraline) (β for change in trend 11.52 (95% CI 
5.32 to 17.73, p<0.001)). Prescribing of other SSRIs and 
tricyclics remained low.
Conclusions Despite a strong emphasis on psychosocial 
interventions for child and adolescent depression, it may 
be that the NICE guidelines inadvertently encouraged 
further antidepressant prescribing, at least for those 
SSRIs cited. Although the guidelines gave cautions and 
caveats for the use of antidepressants, practitioners 
may have interpreted these recommendations as 
endorsing their use in young people with depression and 
related conditions. However, more accurate prevalence 
trend estimates for depression in this age group, and 
information on the use of psychosocial interventions 
would be needed to rule out other reasons underlying this 
increase in prescribing.
IntrOduCtIOn
Depression is a common illness affecting 
approximately 3%–6% of children and adoles-
cents1 and associated with impaired social 
and academic functioning2 3 and increased 
suicide risk.4 However, most depressed adoles-
cents do not receive (specialist) treatment or 
support.5 6 Within primary care settings prac-
titioners are increasingly expected to detect 
child and adolescent depression at the earliest 
possible stage since the severity of depressive 
symptoms appears to correlate with serious 
consequences and negative behaviours.7 
In treating childhood depression (as well as 
other disorders), antidepressants have been 
commonly prescribed.8 During the late 1990s 
and early 2000s, selective serotonin reuptake 
inhibitors (SSRIs) became the preferred 
treatment for depression in children and 
adolescents rather than tricyclic antidepres-
sants.9 However in June 2003, after the reanal-
ysis of published and unpublished data on 
the SSRI paroxetine, the UK Medicines and 
strengths and limitations of this study
 ► The study uses a large and representative national 
dataset.
 ► Analysing the data using an interrupted time series 
regression enabled estimation of the effects of two 
policy changes on the treatment of depression in 
young people in primary care.
 ► Imprecise diagnostic coding in the dataset meant 
we had to take a broad definition of ‘depression’ and 
related conditions.
 ► We could only observe prescriptions issued by pri-
mary care.
 ► For this study, we only had data up to 2010.
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Healthcare Products Regulatory Agency (MHRA) advised 
against its use in the treatment of child and adolescent 
depression.10 The decision was based on the observation 
that the drug was neither efficacious nor safe, with an 
apparent increased risk for self-harm and suicide.11 Later, 
in December 2003, the Committee on Safety of Medicines 
(CSM) reviewed the safety of all antidepressants in under 
18 s and advised against the initiation of venlafaxine and 
all other SSRIs, except fluoxetine.12 These reviews were 
subsequently followed by a ‘black box’ warning from the 
US Food and Drug Administration in 200413 and guide-
lines issued by the UK National Institute for Health and 
Care Excellence (NICE) in 2005.14 The NICE guidelines 
were produced to address the treatment and manage-
ment of depression in children and young people and 
stated that no antidepressant should be used for mild 
depression. Furthermore recommendations were made 
so that psychological therapy should be offered for at 
least 3 months as a first line treatment for moderate to 
severe depression. For patients with inadequate response, 
fluoxetine could be offered in addition to psychological 
therapy to children aged 12–18; for children 5–11, fluoxe-
tine could also be considered but with significant caution. 
In case of fluoxetine non-response or poor tolerability, 
further drug treatment with either sertraline or citalo-
pram could be considered.
Prior to these warnings there was a trend towards 
increased prescribing for child and adolescent depres-
sion. Using data from the UK General Practice Research 
Database (GPRD—now renamed the Clinical Research 
Practice Datalink (CPRD)) to study the prevalence of 
overall antidepressant prescribing from 1992 to 2001, 
Murray and colleagues8 found a 1.7-fold increase in 
prescriptions. In this period, the prevalence of tricyclic 
antidepressant prescriptions decreased by 30% (from 3.6 
per 1000 in 1992 to 2.5 per 1000 in 2001) while SSRI use 
increased 10-fold from 0.5 to 4.6 per 1000 in the same 
time period. The diagnosis of depression in under 18 s 
was associated with the use of SSRIs in 69% of cases. A 
nationally representative US-based survey reported anti-
depressant medication use increased from 0.3 (1987) to 
1.0 (1996) per 100 children and adolescents.15
Several studies investigating changes in prescribing 
trends have been published since the issue of US and 
UK warnings. Using the Disease Analyzer-Mediplus data-
base, Murray and colleagues16 concluded that fewer chil-
dren and adolescents were prescribed antidepressants 
in primary care (6.6 per 1000 in 2000 to 5.7 in 2004). 
More specifically the prevalence of CSM-contraindicated 
antidepressant prescriptions declined by a third (from 
3.1 to 2.0 per 1000) while the prevalence of fluoxetine 
and non-SSRI antidepressants did not increase despite 
the guidance not mentioning these. The study suggests 
that CSM advice had a significant effect in reversing the 
rising prevalence of antidepressant prescribing. These 
findings were later replicated by Wijlaars et al17 who 
demonstrated a significant drop in the rate of depres-
sion diagnoses and SSRI prescriptions around the time 
of the CSM announcement in 2003. However, rates for 
all antidepressants (except paroxetine and imipramine) 
began to rise post-2005. Studies in the Netherlands,18 
USA,19 Australia20 and five Western countries21 have also 
shown that in general these warnings were associated 
with (at least temporary) reductions in the prescribing 
of antidepressants, especially SSRIs. In addition, Bergen 
and colleagues indicated that UK prescriptions of SSRIs 
decreased by 51% following the MHRA warning.22 More 
recently, overall antidepressant prescribing in children 
and adolescents has been shown to have increased in 
Wales23 and the wider UK.24
The aim of the present study was to analyse antide-
pressant prescribing trends, in relation to both the CSM 
warning and publication of NICE guidelines, for chil-
dren and adolescents presenting to UK primary care 
services with depression between January 2000 and June 
2010 using data from the CPRD. Our hypotheses, based 
upon previous research, were that rates of prescribing 
for both NICE ‘approved’ and ‘non-NICE’ SSRIs (that is 
those unmentioned for possible use by the guidelines) 
would decrease following both the CSM warning being 
issued and the publication of NICE guidelines in 2005, 
since these guidelines recommended first line use of 
psychological therapies where possible. In particular we 
expected a marked decrease in the prescription rates for 
antidepressants highlighted by both the CSM and NICE 
as those for which the potential benefits were likely to be 
outweighed by the risks.
MethOds
For the purposes of the study three drug groups were 
investigated: (1) medications named in the NICE Guid-
ance CG28 as suitable for use in young people under the 
age of 18 with depressive illness (fluoxetine, citalopram 
and sertraline); (2) all other non-NICE approved SSRIs 
(paroxetine, fluvoxamine, escitalopram) and (3) tricyclic 
antidepressants (amitriptyline, clomipramine, doxepin, 
imipramine, nortrityline, trimipramine, dosulepin, 
lofepramine).
Rates of primary care issued prescriptions for all medi-
cations listed under section 4.3 of the British National 
Formulary25 as indicated for depressive illness were inves-
tigated. Within the UK approximately 98% of the popula-
tion are registered with a general practitioner.26 We used 
information from the CPRD, which is maintained by the 
MHRA. The CPRD contains anonymised primary care 
records for approximately 5.5% of the UK population 
with data obtained from over 460 primary care practices, 
providing a total of 40 million patient years of clinical 
data.27
Prescription rates
Data were abstracted from the CPRD from GP practices 
where data were classified as ‘up-to-standard’ (UTS) for 
at least 12 months during the study period of 1 January 
2000–30 June 2010. Only data where a patient had a 
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relevant diagnostic code were included (see below). 
Prescribing rates for the three groups of antidepres-
sants were generated by dividing the absolute number of 
depressed children who had a prescription issued (the 
numerator) by the number of under 18 s with depression, 
as defined by the study (see below) within the dataset. 
This fraction was then multiplied by 100 000. Thus, the 
monthly rate reflected the mean number of prescrip-
tions issued per 100 000 affected population. Prescrip-
tion rates were calculated at the individual patient level; 
with repeat prescriptions and instances of re-prescribing 
subsequently removed.
depression and related conditions
Cases were identified as any patient who was recorded as 
having received a first diagnosis of depression before the 
age of 17 within the study timeframe. Individuals were 
excluded from the study if CPRD data were not available 
for a period of 12 months following their 17th birthday. 
This approach was taken in order to reduce the risk of 
underestimating prescribing rates; if a young person of 
this age had a depression-related code they may well have 
had an antidepressant prescribed in the following 12 
months.
The operational definition of ‘depression’ was 
constructed by consensus within the research team using 
CPRD diagnostic (Read/Oxford Medical Information 
System (OXMIS)) codes. Depression is challenging 
to identify and diagnose in children and adolescents 
presenting in a primary care setting.28 29 In an attempt to 
capture the maximum number of ‘true cases’ a wide range 
of CPRD diagnostic codes related to low mood, depres-
sive illness and self-harm were included. See the online 
supplementary file for the full list of the CPRD diagnostic 
codes used for this study. Diagnoses were carried forward 
for each time window so that diagnostic codes were not 
entered on multiple occasions.
statistical analysis
Prescription rates (number of prescriptions per 100 000 
affected population) for 4–17  year olds were calculated 
for each month in the study period for each drug group 
from the CPRD data. The denominator was the number 
of young people in the CPRD data, per month, with a 
diagnosis of depression or related diagnostic code.
Segmented linear regression analyses were performed. 
The magnitude of the slopes observed were formally 
tested in order to assess whether they significantly 
departed from zero. Our segmented regression followed 
the method described by Wagner et al.30 All analyses were 
conducted with STATA V.14.31
ethics
The data were accessed within limits set out by the Medical 
Research Council licence agreement for academic 
access with Medical Research Ethics Committee ethical 
approval. The proposal was approved by the Independent 
Scientific Advisory Committee of the GPRD (protocol 
number 09_075R). In addition the study was exempt from 
external ethical approval on the basis that the data used 
for this study were de-identifiable and routinely collected. 
This was confirmed in writing by the chair of the Durham 
University School of Medicine, Pharmacy and Health’s 
Ethics Committee.
results
Overall the monthly prescription rates observed were very 
low, the highest observed value being for the NICE-rec-
ommended SSRIs in early 2010 at 762 prescriptions per 
100 000 affected 4–18 year olds. The possible reasons for 
these low observed prescribing rates are outlined in the 
discussion section.
Interpretation of model parameters
Segmented regressions with two ‘interruptions’ were 
performed, analysing changes in trend as a result of the 
CSM warning in December 2003 and the publication of 
the NICE guidance in September 2005. The base level 
parameter (β0) gives the rate of prescribing at the start of 
the dataset. The base trend (β1) indicates how prescribing 
patterns were changing prior to the first interruption 
event ie, issuing of the CSM. A positive coefficient indi-
cates an increase in prescribing rate. The post-CSM 
change in level (β2) gives the altered monthly prescribing 
rate following this warning. The post-CSM interruption 
change in trend is denoted by the coefficient β3. The post-
NICE change in level (β4) indicates the altered monthly 
prescribing rate following the publication of the NICE 
guidance. The change in trend following this second 
interruption is denoted by β5.
Prescribing
Impact of CSM warning
The full results are depicted in table 1 and can also be 
visualised in figure 1. Prescription rates of NICE cited 
SSRIs significantly increased in the years leading up to 
the CSM warning (β1= 5.24, 95% CI 3.43 to 7.05, p<0.001). 
This corresponds to a predicted prescription rate per 
month (ppm) per 100 000 depressed 4–18 year olds of 
233 in January 2000, increasing to 474 ppm just before 
the CSM warning. In contrast ‘non-NICE’ SSRIs and tricy-
clic prescription trends were low and stable during this 
period. Following the issuing of the CSM warning only 
the prescribing trends for NICE cited SSRIs appeared to 
change, with a reduced rate (β3= -12.34, 95% CI −18.67 to 
−6.00, p<0.001).
Impact of NICE guidelines publication
As can be seen from table 1 and figure 1, following release 
of the NICE Guidelines, there was a trend for an increase 
in the prescribing rate for NICE cited SSRIs (β5=11.52, 
95% CI 5.32 to 17.73, p<0.001). This equates to a modelled 
rise from 229 ppm at publication of the NICE guidance 
to 531 ppm at the end of the dataset. As can be seen from 
table 1, all three NICE cited SSRIs contributed to this 
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trend, with significant increases in their prescribing rates. 
Non-NICE and tricyclic antidepressant prescribing rates 
appeared unaffected and consistently relatively low.
dIsCussIOn
This is, to our knowledge, the first study evaluating the 
impact of both the CSM warning and NICE guidance 
on antidepressant prescribing trends in young people. 
The findings of this study contradict our hypothesis that 
the publication of the NICE guidelines would result 
in a decrease in both NICE cited and non-cited SSRIs 
prescription rates. Rather, we observed a trend towards 
increased prescription rates. More specifically, prior to 
the CSM warning there was a trend towards increased 
SSRI prescribing, at least for those medications destined 
to be cited by NICE as possible treatments for under 
18 s. Following the warning this trend was reversed, but 
appears to have resumed following publication of the 
NICE Guidelines. Our findings, at least in relation to 
the CSM warning, are in line with previous reports, high-
lighting a temporary reduction in prescription rates for 
antidepressants for under 18 s following such official 
cautions.16–22
One interpretation of these findings is that despite 
a strong emphasis in the NICE guidelines upon using 
psychosocial interventions for child and adolescent 
depression, it may be that this publication inadvertently 
encouraged further antidepressant prescribing. Although 
the guidelines gave cautions and caveats to their use, 
practitioners may have interpreted these recommen-
dations as approval and validation for their widespread 
use. This ‘approval’ interpretation may also have been 
adopted by patients and their carers’ willingness to be 
prescribed these medications. Another factor under-
lying these trends may have been an increased pressure 
for primary care-based clinicians to prescribe SSRIs for 
young people affected by depression, anxiety or other 
mental health indications for the medications, such as 
Obsessive Compulsive Disorder. This could have occurred 
due to challenges with accessing secondary care located 
within Child and Adolescent Mental Health Services 
(CAMHS), for example, with the presence of increasingly 
long waiting lists during that period. Certainly, there 
are indications from ‘CAMHS Benchmarking’ reports 
that waiting lists for such secondary care services have 
increased over time and that, roughly, half of all refer-
rals were not accepted by such teams.32 It also may have 
been that young people were presenting with more severe 
depressive or anxiety symptoms, adding to the pressure to 
prescribe promptly in primary care. It is well established 
that depression, while relatively common in adolescents, 
often presents to primary care under the guise of phys-
ical medical symptoms.33 An increased awareness, and 
changing attitudes towards mental health issues in the 
UK population may also have led to a higher proportion 
of affected young people labelling their difficulties as T
ab
le
 1
 
R
es
ul
ts
 fr
om
 s
eg
m
en
te
d
 r
eg
re
ss
io
n 
an
al
ys
es
 o
f r
at
e 
of
 p
re
sc
rib
in
g 
in
 t
he
 U
K
 in
 4
–1
8 
ye
ar
 o
ld
s
B
as
e 
le
ve
l (
β 0
)
(9
5%
 C
I)
P
 v
al
ue
B
as
e 
tr
en
d
 (β
1)
(9
5%
 C
I)
P
 v
al
ue
P
o
st
-C
S
M
 
in
te
rv
en
ti
o
n 
(β
2)
(9
5%
 C
I)
P
 v
al
ue
P
o
st
-C
S
M
 c
ha
ng
e 
in
 t
re
nd
 (β
3)
(9
5%
 C
I)
P
 v
al
ue
P
o
st
-N
IC
E
 
in
te
rv
en
ti
o
n 
(β
4)
(9
5%
 C
I)
P
 v
al
ue
P
o
st
-N
IC
E
 
ch
an
g
e 
in
 
tr
en
d
 (β
5)
(9
5%
 C
I)
P
 v
al
ue
N
IC
E
 c
ite
d
 S
S
R
Is
23
2.
70
(1
84
.3
3 
to
 2
81
.0
7)
<
0.
00
1
5.
24
(3
.4
3 
to
 7
.0
5)
<
0.
00
1
−
10
7.
94
(−
19
4.
72
 t
o 
−
 2
1.
15
)
0.
02
−
12
.3
4
(−
18
.6
7 
to
 −
 6
.0
0)
<
0.
00
1
52
.7
2
(−
34
.9
5,
 1
40
.4
0)
0.
24
11
.5
2
(5
.3
2 
to
 1
7.
73
)
<
0.
00
1
Fl
uo
xe
tin
e
14
4.
26
(1
12
.6
2 
to
 1
75
.9
0)
<
0.
00
1
2.
10
(0
.9
2 
to
 3
.2
9)
0.
00
1
58
.7
1
(1
.9
4 
to
 1
15
.4
8)
0.
04
−
8.
69
(−
12
.8
3 
to
 −
 4
.5
4)
<
0.
00
1
60
.0
6
(2
.7
1 
to
 1
17
.4
1)
0.
04
7.
97
(3
.9
1 
to
 1
2.
03
)
<
0.
00
1
C
ita
lo
p
ra
m
75
.6
1
(4
7.
99
 t
o 
10
3.
22
)
<
0.
00
1
2.
89
(1
.8
5 
to
 3
.9
2)
<
0.
00
1
−
84
.9
4
(−
13
4.
49
 t
o 
−
 3
5.
40
)
0.
00
1
−
4.
65
(−
8.
27
 t
o 
−
 1
.0
3)
0.
01
44
.4
0
(−
5.
56
, 9
4.
35
)
0.
08
5.
52
(1
.9
8 
to
 9
.0
6)
0.
00
2
S
er
tr
al
in
e
13
.3
1
(−
 3
.6
7 
to
 3
0.
29
)
0.
12
2.
30
(1
.6
7 
to
 2
.9
3)
<
0.
00
1
−
62
.5
7
(−
92
.2
4 
to
 −
 3
2.
90
)
<
0.
00
1
−
3.
26
(−
5.
43
 t
o 
−
 1
.0
9)
0.
00
3
−
16
.0
2
(−
45
.8
4,
 1
3.
80
)
0.
29
2.
51
(0
.3
9 
to
 4
.6
2)
0.
02
N
on
-N
IC
E
 S
S
R
Is
11
6.
40
(1
00
.8
9 
to
 1
31
.9
1)
<
0.
00
1
−
0.
25
(−
0.
83
, 0
.3
4)
0.
41
−
37
.7
8
(−
65
.6
1 
to
 −
 9
.9
5)
0.
01
−
0.
16
(−
2.
19
, 1
.8
8)
0.
88
−
21
.1
2
(−
49
.2
4,
 7
.0
0)
0.
14
0.
61
(−
1.
38
, 2
.6
0)
0.
54
Tr
ic
yc
lic
s
78
.6
5
(5
9.
44
 t
o 
97
.8
5)
<
0.
00
1
0.
55
(−
0.
17
, 1
.2
7)
0.
14
−
0.
96
(−
35
.4
1 
to
 3
3.
49
)
0.
96
−
1.
68
(−
4.
20
, 0
.8
4)
0.
19
−
4.
73
(−
39
.5
4,
 3
0.
08
)
0.
79
1.
89
(−
0.
58
, 4
.3
5)
0.
13
N
IC
E
, N
at
io
na
l I
ns
tit
ut
e 
fo
r 
H
ea
lth
 a
nd
 C
ar
e 
E
xc
el
le
nc
e;
 S
S
R
I, 
se
le
ct
iv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
b
ito
r.
D
urham
. Protected by copyright.
 o
n
 August 21, 2019 at M
s J W
arwick Library, University of
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028201 on 7 August 2019. Downloaded from 
5Tiffin PA, et al. BMJ Open 2019;9:e028201. doi:10.1136/bmjopen-2018-028201
Open access
being primarily psychological in nature, and thus receive 
a primary care antidepressant prescription.34
strengths and limitations
The study uses a large and representative dataset to esti-
mate the effect of policy changes on the treatment of 
depression in young people in primary care. Our method 
of using an interrupted time series regression has also been 
adopted and highlighted as a strength by others analysing 
prescribing trends.22 This study builds on previous 
research into antidepressant prescribing rates in under 
18 s8 16 21–24 by classifying SSRIs into those mentioned in 
the NICE guidance and those not cited. Additionally, by 
modelling an interruption at the time of the release of 
the guidance, we have been able to show trends which are 
consistent with the guidance inadvertently increasing the 
prescribing rates of citalopram and sertraline in partic-
ular. This study thus highlights the potential for clinical 
guidelines to have unintended consequences.
The main limitation to our study was that we observed 
that absolute monthly prescription rates were lower than 
might be anticipated from previous, unrelated studies. 
This raises issues with the precision of either prescribing 
information and/or diagnostic problem category coding 
in our CPRD extract. However, in order to mitigate against 
imprecise diagnostic coding we took a broad definition 
of ‘depression’ and related conditions, including acts 
of self-harm. Nevertheless, we cannot exclude the possi-
bility that some cases were missed. However, assuming 
the ‘measurement error’ was uniform and identically 
distributed throughout the study period the trends we 
elicited should remain valid, even if absolute prescribing 
rates themselves were systematically underestimated. It 
should also be noted that only monthly crude prescrip-
tion rates were used in the trend analysis. Therefore, the 
influence of the same individual being switched from one 
antidepressant to another would not have been captured. 
However, these effects would have been subtle and likely 
to have been swamped by other sources of noise in the 
data, such as reporting accuracy.
It is likely that most psychotropic prescribing occurs in 
secondary care. Thus, our findings may not generalise 
to CAMHS prescribers. Moreover, it was not possible 
to discriminate between prescriptions initiated within 
primary care, and those taken over by practitioners within 
general practice, under the supervision, or at the request 
of CAMHS prescribers. From the data used it was also 
not possible to estimate the role of possible confounders 
in such trends, such as access to psychological therapies 
within the NHS (in spite of the NICE recommendations) 
and possible selection bias of compliance with NICE guid-
ance among CPRD registered practices. It should also 
be noted that some of the tricyclic antidepressants have 
indications other than mental health problems such as 
enuresis (wetting) and neuropathic pain, and may have 
been prescribed for these reasons.
Figure 1 Prescribing rates for NICE cited SSRIs and non-NICE cited SSRIs. Also shown are the intercepts (vertical 
lines) and slopes for the associated segmented regression analyses. NICE, National Institute for Health and Care 
Excellence;SSRI, selective serotonin reuptake inhibitor.
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research and clinical implications
In due course it would be important to analyse data post 
2010 to see if the upward trend in approved SSRI prescrip-
tions has continued and whether this increase is associ-
ated with improved clinical outcomes and suicide rates. 
It would also be useful to complement this analysis with 
referral rates over time for psychological therapies. Qual-
itative research might provide a rich narrative of how the 
guidance was received and interpreted and views about 
the balance of psychotherapeutic and drug intervention.
In terms of clinical implications, previous studies have 
found evidence that the publication of warnings have 
been associated with significant reductions in aggregated 
rates of diagnosis and treatment of paediatric depres-
sion.35 However there may be limitations in continuing 
to extrapolate the CPRD dataset backward or forward 
in time due to changes in GP coding, CPRD diagnostic 
criteria and other contemporaneous clinical and policy 
influences.
Finally, NICE specifically recommends varying the 
approach to treatment according to the severity of depres-
sion. Further more in-depth analysis might consider 
whether the publication of NICE guidance influenced 
prescription rates according to depression severity (mild, 
moderate or severe) and whether certain medications 
were preferred depending upon severity. Unfortunately 
subcategorisation of child and adolescent depression is 
not possible using the CPRD diagnostic codes. We also 
note that, while the changes to the original NICE guide-
lines were minimal, in relation to the update conducted 
in 2017, additional footnotes emphasised that fluoxetine 
was only licensed for the treatment of adolescents with 
depression if a previous trial of a psychological therapy 
had been unsuccessful. Moreover, the absence of specific 
licences for both sertraline and citalopram for the treat-
ment of those under 18 was stressed.36
COnClusIOn
Prescription of NICE cited antidepressants in the UK 
increased significantly between 2005 and 2010, following 
the publication of guidance for children and adolescents 
with depression, following an initial decrease after the 
CSM was issued. The rate of non-NICE recommended 
SSRIs and tricyclics prescriptions before and after publi-
cation remained low. Despite the guidelines strongly 
emphasising the role of psychosocial interventions for 
child and adolescent depression, it may be that the release 
of the NICE publication inadvertently encouraged higher 
rates of antidepressant prescribing, and in particular that 
of sertraline and citalopram. Thus, practitioners possibly 
interpreted these cautious recommendations as endorse-
ments for their use with young people presenting with 
distressing psychological symptoms.
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